Fredrik Berg - Swedish Orphan Executive

BIOVF Stock  USD 26.95  0.84  3.02%   

Executive

Mr. Fredrik Berg is Vice President, General Counsel, Head Legal Intellectual Property, Risk Safety and Environment Management at Swedish Orphan Biovitrum AB . He was employed by the Company since 2001. He started his legal career at the law firm Tisell Co, and later on joined KabiVitrum in 1988. He held various positions such as Company Lawyer and Head of Legal Services at Procordia, Kabi Pharmacia and Pharmacia Upjohn. In 1996, he joined the law firm Lindahl, but was recruited back to Pharmacia in 1997. Prior to joining Biovitrum, he was Head of Legal and Intellectual Property at Pharmacia AB and General Counsel at Pharmacia Europe, Middle East and Africa
Age 61
Phone46 86 97 20 00
Webhttps://www.sobi.com
Berg holds a Master of Legal Letters degree from Stockholms universitet.

Swedish Orphan Management Efficiency

The company has return on total asset (ROA) of 0.0555 % which means that it generated a profit of $0.0555 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1061 %, meaning that it generated $0.1061 on every $100 dollars invested by stockholders. Swedish Orphan's management efficiency ratios could be used to measure how well Swedish Orphan manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 8.78 B in total debt with debt to equity ratio (D/E) of 0.41, which is about average as compared to similar companies. Swedish Orphan Biovitrum has a current ratio of 1.0, suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist Swedish Orphan until it has trouble settling it off, either with new capital or with free cash flow. So, Swedish Orphan's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Swedish Orphan Biovitrum sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Swedish to invest in growth at high rates of return. When we think about Swedish Orphan's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Toby WillardAmerican Express
N/A
Ravi RadhakrishnanAmerican Express
49
Brett LoperAmerican Express
N/A
Edward FaneMorningstar Unconstrained Alloc
N/A
Kevin CoxAmerican Express
53
Rosie PerezAmerican Express
N/A
Manoj AdlakhaAmerican Express
N/A
John MulquineyMorningstar Unconstrained Alloc
N/A
Lisa MarcheseAmerican Express
N/A
Michael LoefflerJpmorgan Equity Index
N/A
Christophe CaillecAmerican Express
57
Kerri BernsteinAmerican Express
N/A
Ken PaukowitsAmerican Express
N/A
Ravikumar RadhakrishnanAmerican Express
52
David FabricantAmerican Express
46
Edward GilliganAmerican Express
54
Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. Swedish Orphan is traded on OTC Exchange in the United States. Swedish Orphan Biovitrum [BIOVF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Swedish Orphan Biovitrum Leadership Team

Elected by the shareholders, the Swedish Orphan's board of directors comprises two types of representatives: Swedish Orphan inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Swedish. The board's role is to monitor Swedish Orphan's management team and ensure that shareholders' interests are well served. Swedish Orphan's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Swedish Orphan's outside directors are responsible for providing unbiased perspectives on the board's policies.
Lennart Johansson, Director
Thomas Larsen, Head Relations
Rami Levin, Head of North America
Dennis Pedersen, Senior Vice President Human Resources
Armin MD, Head Affairs
Alan Raffensperger, COO and Sr. VP
Fredrik Berg, Head of Legal and Intellectual Property, Risk- Safety and Environment Management and General Counsel
BoGunnar Rosenbrand, Director, Employee Representative
Adine Axen, Independent Director
Hakan Bjorklund, Independent Chairman of the Board
Cecilia Forberg, Vice President Head of Project and Portfolio Management
Stephen James, Vice President Head of Drug Design and Development
Bo Hansen, Chairman of the Board
Armin Reininger, Senior Vice President Head of Global Medical and Scientific Affairs
Henrik Stenqvist, Chief Officer
David Allsop, Director
Torbjorn Hallberg, General Counsel and Head of Legal Affairs
Christine Wesstrom, Head Operations
Theresa Heggie, Independent Director
Torbjrn Hallberg, G HR
Hans Wigzell, Independent Director
Annette Clancy, Independent Director
Paula Treutiger, Head of Communications & Investor Relations
Trista Morrison, Vice President - Communications for North America
Daniel Rankin, Head Devel
Kirsti Gjellan, Senior Vice President Manufacturing Operations
Jorgen Winroth, Head of Investor Relations and VP
Milan Zdravkovic, Senior Vice President Head of Research & Development
Norbert Oppitz, Head of Specialty Care
Hans Schikan, Independent Director
Konstantina Karampela, Director Operations
Helena Saxon, Director
Anne Schuermans, Head of Technical Operations
Anders Edvell, Head of Marketing and Sales
Sofiane Fahmy, Head of Southern and Western Europe & North Africa
Pablo Mora, Head Access
Philip Wood, Head of Haemophilia
Geoffrey McDonough, CEO
Lars Dreioee, Senior Vice President Chief Quality & Compliance Officer
Fredrik Wetterlundh, Head of Human Resources
Amy Pott, Head of North America
Birgitte Volck, Senior Vice President Chief Medical Officer
MatsOlof Wallin, CFO, Senior Vice President
Stefan Fraenkel, Vice President Head of Corporate Development
Hege Hellstrom, Head of EMENAR
Catarina Larsson, Director, Employee Representative
Anders MD, Head Officer
Elisabeth Svanberg, Director
Christian Dreger, Head of Northern Europe, Middle East & Russia
Wills HughesWilson, Senior Vice President and Chief Patient Access Officer
Guido Oelkers, President CEO
Pia Axelsson, Director, Employee Representative
Jeffrey Jonas, Independent Director
Matthew Gantz, Director
Pia Axelson, Director, Employee Representative

Swedish Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Swedish Orphan a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Swedish Orphan in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Swedish Orphan's short interest history, or implied volatility extrapolated from Swedish Orphan options trading.

Pair Trading with Swedish Orphan

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Swedish Orphan position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Swedish Orphan will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Swedish Orphan could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Swedish Orphan when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Swedish Orphan - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Swedish Orphan Biovitrum to buy it.
The correlation of Swedish Orphan is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Swedish Orphan moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Swedish Orphan Biovitrum moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Swedish Orphan can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Swedish Orphan Biovitrum. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Swedish Pink Sheet analysis

When running Swedish Orphan's price analysis, check to measure Swedish Orphan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Swedish Orphan is operating at the current time. Most of Swedish Orphan's value examination focuses on studying past and present price action to predict the probability of Swedish Orphan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Swedish Orphan's price. Additionally, you may evaluate how the addition of Swedish Orphan to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Please note, there is a significant difference between Swedish Orphan's value and its price as these two are different measures arrived at by different means. Investors typically determine if Swedish Orphan is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Swedish Orphan's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.